709.13
+12.08(+1.73%)
Currency In USD
| Previous Close | 697.05 |
| Open | 708.8 |
| Day High | 729.04 |
| Day Low | 703.56 |
| 52-Week High | 1,211.2 |
| 52-Week Low | 663.43 |
| Volume | 378,154 |
| Average Volume | 866,861 |
| Market Cap | 76.64B |
| PE | 16.79 |
| EPS | 42.24 |
| Moving Average 50 Days | 721.62 |
| Moving Average 200 Days | 947.15 |
| Change | 12.08 |
If you invested $1000 in Regeneron Pharmaceuticals, Inc. (REGN) 10 years ago, it would be worth $1,713.41 as of February 05, 2025 at a share price of $709.13. Whereas If you bought $1000 worth of Regeneron Pharmaceuticals, Inc. (REGN) shares 5 years ago, it would be worth $1,905.44 as of February 05, 2025 at a share price of $709.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
GlobeNewswire Inc.
Jan 23, 2025 5:00 PM GMT
The Regeneron Science Talent Search Celebrates and Rewards Today’s Most Talented Young Minds Driving Innovation and Progress through Scientific ExplorationTARRYTOWN, N.Y. and WASHINGTON, D.C., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuti
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 13, 2025 11:30 AM GMT
Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 20
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
GlobeNewswire Inc.
Jan 13, 2025 11:15 AM GMT
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo Libtayo is the first and only immunotherapy to sh